Brief report: Clonazepam behavioral side effects with an individual with mental retardation

Journal of Autism and Developmental Disorders

Volumn 33, Issue 3, 2003, Pages 349-354

  Kalachnik, John E ^a,e   Hanzel, Thomas E ^b   Sevenich, Robert ^c   Harder, Stuart R ^d  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Hanzel Consulting ^*  (Czech Republic)

^c UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^d St Croix River Education District   (United States)

^e Iowa Department of Human Services   (United States)

Author keywords

Aggression; Behavioral side effects; Benzodiazepines; Clonazepam; Mental retardation; Side effects

Indexed keywords

ALPRAZOLAM; CLONAZEPAM; DESIPRAMINE; DIAZEPAM; DIPHENHYDRAMINE; GABAPENTIN; GOGENTIN; HALOPERIDOL; LORAZEPAM; PHENYTOIN; PROPRANOLOL; TEMAZEPAM; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; AGGRESSION; AGITATION; ANGER; ARTICLE; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; CASE REPORT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERACTIVITY; IRRITABILITY; MALE; MENTAL DEFICIENCY; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT;

AGGRESSION; ANTICONVULSANTS; CLONAZEPAM; HUMANS; MALE; MENTAL DISORDERS; MENTAL RETARDATION; MIDDLE AGED; SELF-INJURIOUS BEHAVIOR;

EID: 0041706255     PISSN: 01623257     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024466819989     Document Type: Article

References (35)

1. Alvarez, N., Besag, F., & Iivanainen, M. (1998). Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability, Journal of Intellectual Disability Research, 42, (Suppl. 1), 1-15.
2. Aman, M. G., Sarphare, G., & Burrow, W. H. (1995). Psychotropic drugs in group homes: Prevalence and relation to demographic/psychiatric variables. American Journal on Mental Retardation. 99, 500-509.
3. Ashton, H. (1994). Guidelines for the rational use of benzodiazepines. Drugs, 48, 25-40.
4. Awaad, Y., Munoz, S., & Nigro, M. (1999). Progressive dystonia in a child with chromosome 18p deletion, treated with intrathecal baclofen. Journal of Child Neurology, 14, 75-77.
5. Blair, R. J. R., & Curran, H. V. (1999). Selective impairment in the recognition of anger induced by diazepam. Psychopharmacology, 147, 335-338.
6. Bond, A. J. (1998). Drug-induced behavioural disinhibition. Incidence, mechanisms, and therapeutic implications. CNS Drugs, 9, 41-57.
7. Bond, A. J., Curran, H. V., Bruce, M. S., O'Sullivan, G., & Shine, P. (1995). Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. Journal of Affective Disorders, 35, 117-123.
8. Browne, T. R. (1978). Clonazepam. New England Journal of Medicine, 299, 812-816.
9. Commander, M., Green, S. H., & Pendergast, M. (1991). Behavioral disturbances in children treated with clonazepam. Developmental Medicine and Child Neurology, 33, 362-363.
10. Dreifuss, F. E., Penry, J. K., Rose, S. W., Kupferberg, H. J., Dyken, P., & Sato, S. (1975). Serum clonazepam concentrations in children with absence seizures. Neurology, 25, 255-258.
11. Edwards, R. A., & Medlicott, R. W. (1980). Advantages and disadvantages of benzodiazepines. New Zealand Medical Journal, 92, 357-379.
12. Eeg-Olofsson, O. (1973). Experiences with Rivotril® in treatment of epilepsy particularly minor motor epilepsy in mentally retarded children. Acta Neurologia Scandinavica, 49 (Suppl. 53), 29-31.
13. Freinhar, J. P. (1985). Clonazepam treatment of a mentally retarded woman. American Journal of Psychiatry 142, 1513.
14. Gillberg, C. (1991). The treatment of epilepsy in autism. Journal of Autism and Developmental Disorders, 21, 61-77.
15. Golden, A. G., Preston, R. A., Barnett, S. D., Llorente, M., Hamdan, K., & Silverman, M. A. (1999). Inappropriate medication prescribing in homebound older adults. Journal of the American Geriatrics Society, 47, 948-953,
16. Good, D. C., & Howard, H. D. (1982). Myoclonus in Down's Syndrome: Treatment with clonazepam. Archives of Neurology, 39, 195.
17. Graae, F., Milner, J., Rizzotto, L., & Klein, R. G. (1994). Clonazepam in childhood anxiety disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 33, 372-376.
18. Hirvasniemi, A., Herrala, P., & Leisti, J. (1995). Northern epilepsy syndrome: Clinical course and the effect of medication on seizures. Epilepsia, 36, 792-797.
19. Kalachnik, J. E., Hanzel, T. E., Harder, S. R., Bauernfeind, J. D., & Engstrom, E. A. (1995). Antiepileptic drug behavioral side effects in individuals with mental retardation and the use of behavioral measurement techniques. Mental Retardation, 33, 374-382.
20. Khreim, I., & Mikkelsen, E. (1997). Anxiety disorders in adults with mental retardation. Psychiatric Annals, 27, 175-181.
21. Luiselli, J. K., Blew, P., Keane, J., Thibadeau, S., & Holzman, T. (2000). Pharmacotherapy for severe aggression in a child with autism: "Open label" evaluation of multiple medications on response frequency and intensity of behavioral intervention. Journal of Behavior Therapy, 31, 219-230.
22. Nakamura, M., Yamagata, T., Momoi, M. Y., & Yamazaki, T. (1998). Drop episodes in Coffin-Lowry syndrome: Exaggerated startle responses treated with clonazepam. Pediatric Neurology, 19, 148-150.
23. Pary, R. (1993). Psychotropic drugs used with adults and elderly adults who have mental retardation. American Journal on Mental Retardation, 98, 121-127.
24. Physicians' desk reference (54th ed.) (2000). Montvale, NJ: Medical Economics.
25. Pincus, H. A., Tanielian, T. L., Marcus, S. C., Olfson, M., Zarin, D. A., Thompson, J., & Zito, J. M. (1998). Prescribing trends in psychotropic medications. Primary care, psychiatry, and other medical specialties. Journal of the American Medical Association, 279, 526-531.
26. Rosenbaum, J. F., Moroz, G., & Bowden, C. L. (1997). Clonazepam in the treatment of panic disorder with or without agoraphobia: A dose-response study of efficacy, safety, and discontinuance. Journal of Clinical Psychopharmacology, 17, 390-400.
27. Rosenfeld, W. E., Beniak, T. E., Lippmann, S. M., & Loewenson, R. B. (1987). Adverse behavioral response to clonazepam as a function of verbal IQ-performance IQ discrepency. Epilepsy Research, 1, 347-356.
28. Salzman, C., Kochansky, G. E., Shader, R. I., Porrino, L. J., Harmatz, J. S., & Swett, C. P. (1974). Chlordiazepoxide-induced hostility in a small group setting. Archives of General Psychiatry, 31, 401-405.
29. Schenck, C. H., & Mahowald, M. W. (1995). Two cases of premenstrual sleep terrors and injurious sleep-walking. Journal of Psychosomatic Obstetrics and Gynecology, 16, 79-84.
30. Scher, C. S., & Anwar, M. (1999). The self-reporting of psychiatric medications in patients scheduled for elective surgery. Journal of Clinical Anesthesiology, 11, 619-621.
31. Schmidt, E. V., Byars, J. R., & Gruber, J. (2001). Overview of psychotropic and nontraditional medication therapy in a mentally retarded/developmentally disabled population. Consultant Pharmacist, 16, 365-370.
32. Singh, B. K., & Towle, P. O. (1993). Antiepiletic drug status in adult outpatients with mental retardation. American Journal on Mental Retardation, 98 (Suppl.), 41-46.
33. Spreat, S., Conroy, J. W., & Jones, J. C. (1997). Use of psychotropic medication in Oklahoma: A statewide survey. American Journal on Mental Retardation, 102, 80-85.
34. Thompson, T., & Symons, F. J. (1999). Psychotropic medication treatment for destructive behavior based on neurobehavioral mechanisms of drug action. In N. A. Wieseler & R. H. Hanson (Eds.), Challenging behavior of persons with mental health disorders and severe developmental disabilities (pp. 125-150). Washington, DC: American Association on Mental Retardation.
35. Werry, J. S. (1998). Anxiolytics and sedatives. In S. Reiss & M. G. Aman (Eds.), Psychotropic medication and developmental disabilities. The international consensus handbook (pp. 201-214). Columbus: Ohio State University Nisonger Center.